Plant based biopharmaceutical research and medicine developer GB Sciences (OTCMKTS:GBLX) was in the news yesterday following a significant development and that could bring the company’s stock to the radars of investors.
Trading Data
On Tuesday, GBLX stock moved down 2.34% to $0.0250 with more than 154.88K shares, compared to its average volume of 147.52K shares. The stock moved within a range of $0.0250 – 0.0280 after opening trade at $0.0260.
TODAY: Gb Sciences Describes Drug Development Progress in Pharma’s Almanac Journal Article
The company announced that some of the major milestones that it had achieved in recent times with regards to its medicine development pipeline had been published in an article in Pharma’s Almanac. It is a well-known journal in the pharmaceutical industry and the publication of the same presents a significant achievement for Gb Sciences. More importantly, it could lead to greater knowledge about the sort of work that the company has been doing in recent times.
The President and Chief Executive Officer of the company, Dr Andrea Small-Howard spoke about the sort of work that the company has been doing as well. She pointed out that at this point in time, the company was focusing all its resources on getting its Parkinson’s disease products to the clinics.
In addition to that, the new data with regards to the unique anxiety formulations from the company had displayed efficacy in animal model. It now remains to be seen if the Gb Sciences stock comes into focus today or not. It may be a good idea to track the stock today.
Key Quote
“Gb Sciences is focusing considerable resources on bringing our lead Parkinson’s disease formulations to the clinic with promising results already obtained during the formulation of Oral Dissolving Tablets containing our active ingredients for use in human clinical trials,” said Dr. Andrea Small-Howard, President, Chief Science Officer, and Director of Gb Sciences. “We have new data validating the efficacy of our novel anxiety formulations in an animal model, as well as new data demonstrating the improved stability of our oral nanoparticle-encapsulated chronic pain formulations based on newly-adopted manufacturing control processes.”
Technical Data
GBLX stock is trading below the 20-Day and 50-Day Moving averages of $0.0267 and $0. 0258 respectively. Moreover, the stock is trading below the 200-Day moving average of $0. 0281. The company has a total market capitalization of $8.2 million. The stock is down 11% over the past month.
